
CBO Estimate of the Statutory Pay-As-You-Go Effects for Senate Amendment 2122 in the Nature of a Substitute to S. 3187, the Food and Drug Administration Safety and Innovation Act, with Further Amendments Adopted by the Senate Through May 24, 2012

	By Fiscal Year, in Millions of Dollars												2012 -	2012 -
	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2017	2022	
NET DECREASE (-) IN THE DEFICIT														
Statutory Pay-As-You-Go Impact	0	0	-1	-5	-19	-46	-66	-44	-72	-71	-39	-71	-363	
Memorandum:														
Changes in Outlays	0	0	-1	-5	-19	-46	-65	-43	-71	-70	-38	-71	-358	
Changes in Revenues	0	0	0	0	0	0	1	1	1	1	1	0	5	

Source: Congressional Budget Office.

Notes: Components may not sum to totals because of rounding.

The bill would modify how the Food and Drug Administration regulates drugs and devices in a broad range of areas. Several provisions of the bill would affect when lower-priced drugs enter the market. Changing the timing of availability of lower-priced drugs affects spending in federal health programs that pay for prescription drugs and biological products. It would also reduce the costs of health insurance plans and thus reduce federal subsidies for health insurance purchased through an exchange.
